Lenhard Justin R, Nation Roger L, Tsuji Brian T
Laboratory for Antimicrobial Dynamics, NYS Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, Buffalo, NY, USA; School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA; California Northstate University College of Pharmacy, Elk Grove, CA, USA.
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Int J Antimicrob Agents. 2016 Dec;48(6):607-613. doi: 10.1016/j.ijantimicag.2016.09.014. Epub 2016 Oct 24.
The proliferation of extensively drug-resistant Gram-negative pathogens has necessitated the therapeutic use of colistin and polymyxin B. However, treatment failures with polymyxin monotherapies and the emergence of polymyxin resistance have catalysed the search for polymyxin combinations that synergistically kill polymyxin-susceptible and -resistant organisms. This mini-review examines recent (2011-2016) in vitro and in vivo studies that have attempted to identify synergistic polymyxin combinations against Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii. Clinical evidence for the use of combination regimens is also discussed.
广泛耐药革兰氏阴性病原体的扩散使得黏菌素和多黏菌素B的治疗应用成为必要。然而，多黏菌素单药治疗的失败以及多黏菌素耐药性的出现促使人们寻找能够协同杀死对多黏菌素敏感和耐药菌株的多黏菌素联合用药方案。本综述探讨了近期（2011 - 2016年）针对铜绿假单胞菌、肺炎克雷伯菌和鲍曼不动杆菌，试图确定具有协同作用的多黏菌素联合用药方案的体外和体内研究。还讨论了联合用药方案使用的临床证据。
